Biodelivery Sciences International Inc (BDSI): Francis E Jr Odonnell , director of Biodelivery Sciences International Inc sold 100,000 shares on Sep 22, 2016. The Insider selling transaction was reported by the company on Sep 23, 2016 to the Securities and Exchange Commission. The shares were sold at $2.57 per share for a total value of $256,500.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 23, 2016, Niraj Vasisht (Chief Technology Officer) sold 47,000 shares at $2.54 per share price.On Aug 12, 2016, William B Stone (director) sold 16,000 shares at $2.57 per share price.Also, On Mar 23, 2016, Charles Bramlage (director) purchased 8,850 shares at $2.82 per share price.On Mar 22, 2016, Barry I Feinberg (director) purchased 10,000 shares at $2.74 per share price.
BioDelivery Sciences International: On Thursday, Sep 22, 2016 heightened volatility was witnessed in BioDelivery Sciences International which led to swings in the share price. The shares opened for trading at $2.47 and hit $2.51 on the upside , eventually ending the session at $2.45, with a gain of 0.82% or 0.02 points. The heightened volatility saw the trading volume jump to 5,51,934 shares. The 52-week high of the share price is $7.79 and the company has a market cap of $131 M . The 52-week low of the share price is at $1.86.
BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.